Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for Giant Cell Arteritis
2023-505476-29-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) comparing Upadacitinib + prednisolone taper with Placebo + prednisolone taper (2 arms). Primary endpoint: Sustained remission at Week 52. Started Jul 2024; status: completed.
02
Drugs
upadacitinib
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2023-505476-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505476-29-00.